McGill University has contributed significantly to venous thrombosis research through the COBRRA trial, demonstrating the safety of apixaban over rivaroxaban.
McGill University has contributed significantly to venous thrombosis research through the COBRRA trial, demonstrating the safety of apixaban over rivaroxaban.